|Product Pipeline |Product Portfolio |
| Cardiovascular Diseases | Central Nervous System Disorders | Infectious Diseases | | Arthritis/Inflammation| Metabolic Diseases | Allergic Diseases | | Cancer | Genitourinary/Sexual Health | Surgery/Interventional | | Consumer Health/OTC | Animal Health | | |
MAJOR PFIZER PRODUCTS AND SELECTED CANDIDATES IN DEVELOPMENT | ||
Central Nervous System Disorders | ||
Current Products | ||
Aricept (donepezil)2 (for Alzheimers disease) Atarax/Vistaril Navane Sinequan Zoloft (for depression, OCD, and panic disorder) Zoloft [U.S.] (for pediatric OCD) |
||
Extensions / Additional Indications (last 12 months) | Under Regulatory Review | In Advanced-Stage Development |
Zoloft (for panic disorder) Zoloft [U.S.] (for pediatric OCD) |
Zeldox (ziprasidone) (for psychosis) Zeldox Intramuscular (IM form of ziprasidone) (for agitated psychotic patients) |
eletriptan (for acute migraine) Zoloft (for PTSD) Zoloft liquid oral concentration |
Key: [U.S.]U.S. only    [I]International only (in at least one country) No KeyBoth U.S. and at least one other country 2Copromoted by Eisai and Pfizer; trademark of Eisai | ||
Advisory Information for Investors | ||||
Copyright © 1997, 1998 Pfizer Inc All rights reserved. | ||||